1

Matters of Administration

1.1

Welcome and apologies

1.2

Minutes and recommendations of the 165th MARC meeting

1.3

Declaration of potential conflicts of interest

2

Medsafe Pharmacovigilance Activities

2.1

Report on standing agenda items

2.2

Medsafe pharmacovigilance activities

2.3

Prescriber Update

2.4

Quarterly summary of recent safety communications

3

Pharmacovigilance Reports

3.1

Matters referred to the MARC under section 36 of the Medicines Act 1981

3.2

Matters referred to the MARC by Medsafe

3.2.1

Use of dexchlorpheniramine and other sedating antihistamines in children

3.2.2

Loratadine and desloratadine: review of sedation warning

3.2.3

Use of tramadol in children

3.2.4

Risk of chronic kidney disease in patients taking proton pump inhibitors 

3.2.5

Risk of dementia in patients taking proton pump inhibitors
 

4

Matters Arising from the NZ Pharmacovigilance Centre

4.1

CARM Quarterly Report

5

Other Business

5.1

Handbook Updates

5.2

Use of Quickr

5.3

Therapeutic products regulation project – Update